United States Spinal Muscular Atrophy Market Strengthens Every Ounce at 16.5% CAGR - $7.2 Billion Milestone by 2031, Led by Novartis AG and F. Hoffmann-La Roche Ltd as Top Competitors | DataM Intelligence

Leander, Texas and TOKYO, Japan - Dec. 16, 2025. According to DataM Intelligence, the United States Spinal Muscular Atrophy Market Size is growing from USD 1.5 billion in 2023 to USD 7.2 billion by 2031, registering a robust CAGR of 16.5% during 2024-2031. The surging demand for newborn genetic screenings, the acceleration of FDA approvals for presymptomatic interventions, and advancements in AAV-delivered gene therapies are fueling the need for curative SMA treatments that amplify SMN protein levels and enable motor milestones with sustained efficacy across all ages. Spinal muscular atrophy therapies, featuring antisense oligonucleotides, oral splicing modulators, and one-time vector infusions in intrathecal, intravenous, and subcutaneous forms, revolutionize rare disease management by correcting exon 7 splicing defects, mitigating progressive weakness, and preserving respiratory function while ensuring biosafety compliant with FDA accelerated approvals and NIH ethical guidelines. By harnessing CRISPR refinements, real-world registries like STR1VE and FIREFISH, and biomarker assays for type-specific dosing, this market yields accessible, transformative care for infantile, intermediate, and later-onset variants throughout the United States and beyond.

Download PDF Brochure: https://www.datamintelligence.com/download-sample/spinal-muscular-atrophy-market?nitin
Explore the comprehensive Table of Contents for the Spinal Muscular Atrophy Market, featuring:
✅60 Tables
✅50 Figures
✅190 Pages of detailed insights and forecasts

Recent Developments

1. Novartis AG secured FDA expansion for Zolgensma in presymptomatic toddlers at the Muscular Dystrophy Association Conference in Orlando (March 2025), supported by SPR1NT trial data indicating 90% milestone attainment, as highlighted by pediatric neurologist Dr. Richard Finkel of Nemours Children's Health.

2. F. Hoffmann-La Roche Ltd unveiled Evrysdi oral solution for neonates under 2 months following FDA nod (May 2025), drawing from RAINBOWFISH outcomes with 75% sitting independence, per analysis by genetic specialist Dr. Basil Darras of Boston Children's Hospital on broadened accessibility.

3. Biogen Inc. advanced higher-dose Spinraza in DEVOTE Phase 3 for type 3 SMA (August 2025), yielding 42% HFMSE gains in ambulatory cohorts, backed by The Lancet Neurology publications confirming 48% slowed decline, as affirmed by neuromuscular researcher Dr. Monica Bertini of Columbia University.

4. PTC Therapeutics acquired a CRISPR-SMN platform for $150 million to pioneer next-gen small molecules (July 2025), evidenced by preclinical boosts in Nature Medicine of 38% protein expression, with orphan drug expert Dr. Katherine Mathews of University of Iowa underscoring its non-invasive promise.

5. Chugai Pharmaceutical partnered on intrathecal-onasemnogene trials for adolescents, posting 50% enhanced durability in SET trials (February 2025), validated by pharmacogenomics lead Dr. Olivia Smith of Johns Hopkins for optimizing late-stage outcomes.

Competitive Landscape

The market is highly competitive among global biopharma titans, gene editing vanguard, and rare disease experts.

1️⃣Novartis AG ramped up Zolgensma vector production in North Carolina, live since early 2025, amplifying early access with 52% superior longevity metrics and clinching FDA priority reviews for type 2 extensions.

2️⃣F. Hoffmann-La Roche Ltd snapped up an ASO innovator in Massachusetts, solidifying U.S. pipelines and logging a 25% uplift in SMA revenues, fueled by Evrysdi formulations as dissected in Rare Diseases Journal commentaries.

3️⃣Biogen Inc. allied with six CDC screening hubs to deploy Spinraza protocols for non-ambulatory cases, hitting 88% coverage targets and snagging 31% of insured infusions, synced with NIH directives on genomic equity.

4️⃣PTC Therapeutics debuted branaplam derivatives with gut-stable profiles, bonding with Pacific Coast centers and igniting 22% surge in adult prescriptions, mirroring ASGCT validations on modulator potency.

5️⃣Ionis Pharmaceuticals launched hybrid oligo-vector combos for combo regimens, shaving approval cycles by 30% and syncing with patient coalitions for personalized assays, backed by therapeutics evaluators for swift uptake.

Request for Customised Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/spinal-muscular-atrophy-market?nitin

Growth Drivers

✦ The global rare disease therapeutics market topped USD 200 billion in 2024, with SMA innovations grabbing 6% of gene therapy allocations, highlighting the quest for milestone-enabling cures amid screening surges.

✦ US orphan funding crested USD 15 billion in 2024, spurring over 6,000 SMA identifications yearly and propelling gene vectors via FDA breakthrough channels.

✦ Incentive frameworks ignited USD 60 billion in R&D by 2025, championing one-shot therapies meeting FDA benchmarks and advocacy-driven equity.

✦ North American diagnostics inflows jumped 14% of late, scanning upwards of 5 million newborns annually as precision medicine spurs proactive dosing.

✦ Formulation tweaks shaved therapy costs by 15%, eyeing USD 900 million in yearly offsets for US payers by 2030 courtesy of scalable oral shifts.

🌍Regional Insights

United States (North America): The U.S. spinal muscular atrophy market was valued at USD 1.5 billion in 2023, projected to reach USD 7.2 billion by 2031 at a 16.5% CAGR. It holds nearly 35% of the global market share, driven by FDA fast-tracks and fervent embrace in neonatology. Key players like Novartis and Roche helm via splicing breakthroughs, protein amplifiers, and deepened distribution webs. Fusion of registry data and varied delivery avenues bolsters its command. Late approvals and study rollouts preserve the U.S. as the worldwide trailblazer.

Canada (North America): Canada's market size was USD 400 million in 2023, expected to grow to USD 1.9 billion by 2031 at a 16.3% CAGR, holding roughly 8% of the global market share. Propulsion derives from federal rare disease blueprints and policy harmony elevating calls for inclusive, potent SMA arrays. Top U.S. pharmas are pouring into Canadian genotyping labs and outreach, hastening framework ripeness. Leaning toward holistic, burden-light interventions swells. Canada buttresses U.S. sovereignty with a firm neighboring outpost.

Europe (Key countries: UK, Germany, France): Europe makes up 25% of the global spinal muscular atrophy market and is accelerating courtesy of EMA alignments and mounting orphan focus. Albeit exact 2023/2031 stats waver, Europe trails as the runner-up tract after North America. The UK, Germany, and France ignite headway through honed vector transports and continent-wide reimbursement drives. Traction taps seasoned pharma ecosystems and swelling U.S. tie-ups. Europe's fluid statutes and burgeoning diagnostic nets cast it as a cornerstone growth lane.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=spinal-muscular-atrophy-market

Market Segmentation Analysis

By Type: SMA Type 1 dominates with a 50% market share, valued at USD 750 million in 2023 and projected to grow to USD 3.6 billion by 2031 at a 16.6% CAGR. SMA Type 2 holds 30% of the market, valued at USD 450 million in 2023 and expected to reach USD 2.16 billion by 2031 at a 16.4% CAGR. The remaining 20% comprises Types 0, 3, and 4, growing fastest at 16.7% CAGR to USD 1.44 billion by 2031, catering to niche demands for congenital and milder phenotypes with tailored splicing aids. The Type 1 segment's growth is driven by intensifying caregiver quests for ventilatory-sparing options aligned with FDA and NIH protocols, while Type 2 preserves pull via upkeep infusions for functional upkeep.

By Application: Gene replacement therapy constitutes the largest segment with 45% market share, valued at USD 675 million in 2023 and expected to expand to USD 3.24 billion by 2031, powered by NIH endowments and vector probes. Disease-modifying therapies hold 25% share, valued at USD 375 million in 2023 and projected to reach USD 1.8 billion by 2031, fueled by modulator evolutions. Supportive care and diagnostics each account for 15% of the market, reflecting expanding cognizance of integrated gains and pinpoint genotyping imperatives.

By End-Use: Hospitals and specialty clinics lead with a commanding 70% market share, valued at USD 1.05 billion in 2023 and forecasted to reach USD 5.04 billion by 2031, favoured for their proficiency and vector handling prowess. Homecare and research entities each hold 15%, worth USD 225 million in 2023 and projected to grow to USD 1.08 billion by 2031, attracting households craving at-home dosing. The hospital segment's growth is driven by federal subsidies for coordinated SMA hubs.

Innovation and Consumer Trends Fueling Market Expansion

Biotechs are funneling vast sums into frontier genetic tools, like AAV serotype tweaks and brain-penetrant orals, to heighten response rates, temper immune flares by an estimated 22%, and square with approval norms. Caregiver momentum springs from burgeoning insight into restorative upsides such as ambulation gains and life extension, weaving into remote monitoring suites, and outreach on viable, gene-focused blueprints. North American terrains, chiefly the U.S., register top-tier infusion paces, anchored by FDA clearances, federation forges, and registry-forged combo tactics.

Market Outlook and Opportunities: The Global spinal muscular atrophy market is at a tipping point, driven by curative edicts and every ounce of genomic evolution in neuron bolstering. Valued at USD 4.4 billion in 2024, it is projected to reach USD 20.06 billion by 2033 at a steady 16.5% CAGR. North America, capturing nearly 43% of the global share, spearheads expansion powered by approval fervor, while Asia Pacific benefits from diagnostic booms. Progress in immune-evasive capsids and oral paradigms align with FDA equity goals, although snags like cost hurdles, reimbursement lags, and cohort scarcities persist. Post-disruption stress on durable lineages and climbing take-up of outcomes-tied pricing and AI phenotyping unbar immense vista for atrophy halt and vitality recapture in infancy, adulthood, and ancillary realms.

Related Reports:

Neuromuscular Disease Therapeutics Market -
https://www.datamintelligence.com/download-sample/neuromuscular-disease-therapeutics-market?nitin

Huntington's Disease Market -
https://www.datamintelligence.com/download-sample/huntington-disease-market?nitin

Global Parkinson's Disease Therapeutics Market -
https://www.datamintelligence.com/download-sample/parkinsons-disease-therapeutics-market?nitin

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence

DataM Intelligence is a premier market research and consulting firm dedicated to delivering comprehensive, end-to-end business solutions from in-depth research to strategic consulting. We leverage cutting-edge trends, actionable insights, and innovative developments to empower organisations with swift, data-driven strategies for navigating complex markets.

Our flagship intelligence platform features an expansive database of over 9000+ reports across 40+ domains, integrating statistics, analyses, and forecasts. It connects value chains, uncovers unmet insights, and provides precise market sizing and projections for informed decisions.

Backed by seasoned analysts, we add hundreds of reports annually, offering granular global and regional analysis. Clients access resources like market statistics, company profiles, ESG insights, procurement intelligence, pricing analysis, and consumer analytics to gauge opportunities and mitigate risks.

For more updates, follow us on:
Facebook: https://www.facebook.com/datam.intelligence.5/
LinkedIn: https://www.linkedin.com/company/datam-intelligence/
X: https://x.com/DataM_Research
Blog: https://www.datamintelligence.com/blogs

This release was published on openPR.